<DOC>
	<DOCNO>NCT01736410</DOCNO>
	<brief_summary>To explore overall response rate trastuzumab combine TS-ONE base chemotherapy first-line HER2-positive advance gastric cancer .</brief_summary>
	<brief_title>A Phase 2 Study Trastuzumab Combination With TS-ONE Cisplatin Firstline Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Advanced Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Patients must histologically cytologically confirm adenocarcinoma stomach Gastricesophageal junction . 2 . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) equal 20 mm conventional technique equal 10 mm spiral CT scan . 3 . Patients without prior systemic treatment . Patients complete postoperative adjuvant chemotherapy ( radiotherapy ) 180 day may enrol . 4 . Age equal 21 year . 5 . Life expectancy great 3 month . 6 . ECOG performance status less equal 2 ( Karnofsky equal 60 % ) . 7 . Patients must normal organ marrow function define : Hemoglobin &gt; 8.0 g/dL Leukocytes &gt; 3,000/mcL Absolute neutrophil count &gt; 1,500/mcL Platelets &gt; 100,000/mcL Total bilirubin less equal 1.5 X ULN AST ( SGOT ) /ALT ( SGPT ) less equal 3 x institutional upper limit normal ALP le equal 3 x upper limit normal* Creatinine within normal institutional limit OR Creatinine clearance** &gt; 60 mL/min patient creatinine level institutional normal In presence liver metastasis , patient AST , ALT ALP &lt; = 5 x upper limit normal may admit . *In presence bone metastasis , patient AST , ALT ALP &lt; = 10x upper limit normal maybe admit . ** : Creatinine clearance estimate use CockcroftGault formula man : Ccr ( mL/min ) = body weight ( kg ) x ( 140 age ) / ( 72 x serum creatinine ( mg/dL ) ) , woman : Ccr = male Ccr x 0.85 ] . The CrCl Formula apply site . 8 . Patients HER2positive cancer confirm IHC and/or FISH*** . *** Immunohistochemistry ( IHC ) HER2 routine part pathological evaluation gastric hybridisation ( FISH ) Her2 copy number require . A copy number value 2.2 take positive . The sponsor drug use investigator initiated trial ( Taiho ) kindly agree pay HER2 FISH test . 9 . Patients able take orally . 10 . Patients leave ventricular ejection fraction least 50 % MUGA 2Dechocardiography do within 28 day enrollment . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 11 . The effect propose regimen develop human fetus recommend therapeutic dose unknown . For reason antitumor agent well therapeutic agent use trial know teratogenic , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . 12 . Ability understand willingness sign write informed consent document . 13 . Consent fresh frozen tissue collection , mandatory patient primary insitu tumor optional patient without primary insitu tumor . Tissue collection applicable National Cancer Centre ( S ) National University Hospital ( S ) 1 . Patients radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due treatment administer 4 week earlier . 2 . Patients receive investigational agent . 3 . Patients know brain metastasis . 4 . History allergic reaction attribute compound similar chemical biologic composition TSONE , cisplatin trastuzumab agent use study . 5 . Presence contraindication TSONE cisplatin trastuzumab . 6 . Baseline LVEF ( Left Ventricular Ejection Fraction ) &lt; 50 % . 7 . Patients serious ( e.g.inpatient care need ) complication ( e.g . intestinal paralysis , intestinal occlusion , interstitial pneumonia pulmonary fibrosis , poorlycontrolled diabetes , renal failure hepatic cirrhosis ) . 8 . Patients massive ascites ( moderate high , beyond pelvic cavity retention anterior surface liver CT ) massive pleural effusion retention . 9 . Patients fresh bleed digestive tract need repeat blood transfusion . 10 . Patients diarrhea ( 4 time per day watery diarrhea ) . 11 . Previous malignancy gastric cancer diagnose last 5 year except basal cell carcinoma skin preinvasive cancer cervix . 12 . Patients reproductive potential refuse use adequate mean contraception ( include male patient ) . 13 . Significant disease condition , investigator 's opinion , would exclude patient study . 14 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 15 . Pregnant lactate female . 16 . HIVpositive patient .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>